Core Viewpoint - Zhonghui Biotech-B (02627) has received approval from the National Medical Products Administration of China for its quadrivalent influenza virus subunit vaccine aimed at the 6-35 month age group, marking it as the first and only approved vaccine of its kind in China for the entire population and all dosage levels [1] Company Overview - The company is headquartered in China and focuses on the research, development, manufacturing, and commercialization of innovative vaccines and traditional vaccines using new technological methods [1] - The company tracks global infectious disease incidence and vaccine development trends to determine its product pipeline, emphasizing high-quality vaccines to replace traditional and imported vaccines in China while expanding its competitive advantage to international markets [1] Product Details - The newly approved quadrivalent influenza virus subunit vaccine is a significant upgrade over traditional virus split vaccines, offering comprehensive protection, high purity of antigen components, and lower risk of adverse reactions [1] - The company's product line includes the quadrivalent influenza virus subunit vaccine, a lyophilized human rabies vaccine under development, and other vaccines in the pipeline [1]
中慧生物-B(02627)：四价流感病毒亚单位疫苗的上市申请获国家药监局批准